

## Product Information

## Anti-Gliadin (Wheat)–Peroxidase Conjugate Antibody Produced in Rabbit

Fractionated antiserum, PBS solution

**A1052**

### Product Description

Anti-Gliadin is produced in rabbit using purified gliadin (prolamin from wheat) as the immunogen. The fractionation procedure yields primarily the immunoglobulin fraction of antiserum. The antibody is conjugated to horseradish peroxidase by a two-step glutaraldehyde procedure. The product is purified to remove unconjugated material.

Rabbit Anti-Gliadin shows a greater specificity for native gliadin than for heat treated gliadin. The conjugate reacts with prolamin fractions of rye, barley, soy and oats. No cross reactivity is observed in such extracts from rice or potato.

The alcohol soluble proteins (prolamins) from wheat, rye, barley and oats produce the harmful effect of coeliac disease or gluten-sensitive enteropathy in humans by causing characteristic changes in the intestinal mucosa. Patients so affected have to avoid eating these grains and replace them with rice, corn, soy, potatoes, etc. Many gluten-free foods are produced industrially; thus several immunoassays have been developed for the determination of gliadin in supposedly gluten-free foods.

### Reagent

Reagent Supplied as a Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 1% bovine serum albumin and 0.05% MIT.

### Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses.

### Storage

For continuous use, store at 2-8 °C for up to one month. For extended storage, the solution may be frozen in working aliquots. Repeated freezing and thawing, or storage in "frost-free" freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use.

## Product Profile

Protein Content: 10-20 mg/mL by absorbance at 280 nm.

Molar Ratio (Antibody/Enzyme): 0.6-1.5

### Direct ELISA

A minimum dilution of 1:1,000 is determined by direct ELISA using gliadin at 5 µg/mL in carbonate/bicarbonate buffer, pH 9.5 as the coating solution.

### Substrate

*o*-Phenylenediamine Dihydrochloride (OPD), 0.4 mg/mL in phosphate citrate buffer with sodium perborate. OPD is available as P6912, and Phosphate Citrate Buffer with Sodium Perborate is available as P4922.

### Dot Blot

A minimum dilution of 1:500 was determined in a direct dot blot using a 2-4 µL dot of gliadin at a concentration of 0.25-0.5 mg/mL or 1:150-1:300 dilution of sample extract.

**Note:** In order to obtain best results, it is recommended that each individual user determine their working dilution by titration assay.

## Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

### Technical Assistance

Visit the tech service page at [SigmaAldrich.com/techservice](https://SigmaAldrich.com/techservice).

### Terms and Conditions of Sale

Warranty, use restrictions, and other conditions of sale may be found at [SigmaAldrich.com/terms](https://SigmaAldrich.com/terms).

### Contact Information

For the location of the office nearest you, go to [SigmaAldrich.com/offices](https://SigmaAldrich.com/offices).

The life science business of Merck operates  
as MilliporeSigma in the U.S. and Canada.

Merck and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2020-2024 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

A1052pis Rev 09/24

